Samuel Perry

Samuel Perry has a wealth of experience in operations and research. From 2022 to 2021, they served as Senior Director of Operations at Remix Therapeutics and as Director, Laboratory & Facilities Operations at Ensoma. From 2015 to 2010, they were Senior Director, Operations and Associate Director, Operations at Compass Therapeutics LLC. At MedImmune, they were an Associate Scientist I and R&D Associate II, where they were a key team member of multiple antibody-drug conjugate (ADC) programs, two bispecific antibody programs, and a blood-brain barrier (BBB)-penetrating antibody program. Samuel also developed a system to track laboratory expenses, initiated and established partnerships, drafted contracts, and recruited and trained college interns. From 2007 to 2006, they were a Senior Research Technician and Research Technician at Dana-Farber Cancer Institute and a Research Technician II at Harvard Medical School.

Samuel Perry attended The Johns Hopkins University - Carey Business School from 2011 to 2014, where they earned a Master of Business Administration (MBA). Samuel also attended The Johns Hopkins University from 2011 to 2014, where they earned a Master of Science (M.S.) in Biotechnology. Prior to this, they attended St. Lawrence University from 2001 to 2005, where they earned a Bachelor of Science (B.S.) in Neuroscience.